281 completed, 47 recruiting, 36 unknown, 27 terminated. 443 Phase 1, 107 Phase 2.
Follow Parkinsonian Disorders: new trials by email Literature Review of Parkinsonian Disorders trials Research Report on Parkinsonian Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies | Phase 1 / Phase 2 | Not yet recruiting | Qiang Zhang | 40 | 2027-10-01 | 2026-03-12 |
| Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease Fecal Microbiota Transplant - Parkinson Disease | Phase 1 | Not yet recruiting | ProgenaBiome | 10 | 2027-07-01 | 2026-10-09 |
| Sustained Release Oral Formulation For Treatment Of Parkinsons Disease Formulation A, Formulation B, Formulation C - Healthy Volunteers | Phase 1 / Phase 2 | Not yet recruiting | University of Minnesota | 32 | 2027-04-01 | 2026-10-01 |
| Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), Advanced Primary PD | Phase 1 / Phase 2 | Not yet recruiting | Kanglin Biotechnology (Hangzhou) Co., Ltd. | 12 | 2027-01-01 | 2026-11-16 |
| ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease ZR001 - Parkinson's Disease (PD), Parkinsonian Disorders | Phase 1 | Not yet recruiting | Qianfoshan Hospital | 8 | 2026-12-01 | 2026-07-22 |
| Coordinated Reset Deep Brain Stimulation for Parkinson's Disease DBS - Parkinson's Disease (PD), Deep Brain Stimulation | Phase 1 | Not yet recruiting | University of Minnesota | 24 | 2026-12-01 | 2026-10-13 |
| Stanford University Neurofiber Study Prebiotic fiber bar - PARKINSON DISEASE (Disorder) | Phase 1 | Not yet recruiting | Stanford University | 50 | 2026-12-01 | 2026-11-03 |
| A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), PD | Phase 1 / Phase 2 | Not yet recruiting | Kanglin Biotechnology (Hangzhou) Co., Ltd. | 12 | 2026-12-01 | 2026-11-10 |
| A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS NCR201 - PARKINSON DISEASE (Disorder), Cell Therapy | Phase 1 | Not yet recruiting | Nuwacell Biotechnologies Co., Ltd. | 12 | 2026-11-01 | 2026-10-26 |
| AAV2-hAADC for Parkinson's Disease (PDCS-01) AAV2-hAADC - Parkinson's Disease (PD), Early Onset Parkinson Disease | Phase 1 | Not yet recruiting | Russell Lonser | 9 | 2026-11-01 | 2026-11-03 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease UX-DA003 - Parkinson's Disease | Phase 1 / Phase 2 | Recruiting | Shanghai UniXell Biotechnology Co., Ltd | 12 | 2026-09-24 | 2026-11-04 |
| Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease TRB-001, Placebo - Parkinson Disease (PD), Idiopathic Parkinson's Disease | Phase 1 | Recruiting | Tridem Bioscience FlexCo | 36 | 2026-09-01 | 2026-09-24 |
| Terazosin And Metabolic Engagement in Parkinson's Disease Terazosin Hydrochloride, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Withdrawn | Nandakumar Narayanan | 2026-09-01 | 2026-10-07 | |
| MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD) [¹⁸F]MK-0947 - Parkinsons Disease (PD), Healthy Elderly Volunteers | Phase 1 | Recruiting | XingImaging, LLC | 18 | 2026-08-25 | 2026-10-19 |
| An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination. TRB-001 - Parkinson's Disease | Phase 1 | Recruiting | Tridem Bioscience FlexCo | 6 | 2026-07-28 | 2026-09-10 |
| A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA SST001 - Multiple System Atrophy (MSA), Parkinson's Disease (PD) | Phase 1 | Recruiting | Synusight Biotech (Shanghai) Co., Ltd. | 30 | 2026-06-15 | 2026-09-01 |
| A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study) MF-1, Placebo - Healthy Adult Male, PARKINSON DISEASE (Disorder) | Phase 1 | Recruiting | University of Shizuoka | 58 | 2026-06-01 | 2026-06-24 |
| A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD) Lu AF28996 - Parkinson Disease | Phase 1 | Recruiting | H. Lundbeck A/S | 10 | 2026-05-26 | 2026-08-10 |
| A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations VGN-R08b 4.2×10^13 vg, VGN-R08b 8.4×10^13 vg, VGN-R08b 1.68×10^14 vg - Parkinson Disease (PD) | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Vitalgen BioPharma Co., Ltd. | 17 | 2026-05-25 | 2026-05-01 |
Showing 20 of 443. Sign in to see all of them.
Parkinson Disease (436) · Movement Disorders (19) · Alzheimer Disease (18) · Neurodegenerative Diseases (16) · Multiple System Atrophy (13) · Dyskinesias (11) · Lewy Body Disease (10) · Brain Diseases (8) · Central Nervous System Diseases (7) · Cognitive Dysfunction (7) · Depression (6) · Nervous System Diseases (6) · Parkinson Disease 4, Autosomal Dominant Lewy Body (6) · Amyotrophic Lateral Sclerosis (4)
Basal Ganglia Diseases (440) · Synucleinopathies (440) · Nervous System Diseases (437) · Central Nervous System Diseases (436) · Brain Diseases (435) · Neurodegenerative Diseases (426) · Movement Disorders (424) · Mental Disorders (34) · Neurocognitive Disorders (32) · Pathological Conditions, Signs and Symptoms (32) · Signs and Symptoms (28) · Dementia (24) · Neurologic Manifestations (24) · Autonomic Nervous System Diseases (15)
opicapone (29) · carbidopa, levodopa drug combination (21) · Levodopa (14) · Carbidopa (12) · rotigotine (12) · entacapone (11) · nebicapone (9) · benserazide, levodopa drug combination (6) · Resveratrol (4) · Sodium Chloride (4) · rasagiline (4) · 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (3) · 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (3) · Acetylcysteine (3) · Rifaximin (3)
Bial - Portela C S.A. (44) · Luye Pharma Group Ltd. (11) · Institute for Neurodegenerative Disorders (9) · H. Lundbeck A/S (8) · National Institute of Neurological Disorders and Stroke (NINDS) (8) · NeuroDerm Ltd. (7) · AbbVie (5) · Affiris AG (5) · Kyowa Kirin Co., Ltd. (5) · Merck Sharp & Dohme LLC (5) · Pfizer (5) · University of Minnesota (5) · Craig van Horne, MD, PhD (4) · Herantis Pharma Plc. (4) · Neurocrine Biosciences (4)
United States (197) · China (38) · United Kingdom (30) · France (22) · Portugal (16) · Germany (15) · Netherlands (15) · Canada (14) · Japan (14) · Sweden (10) · Finland (9) · Australia (8) · Israel (8) · Austria (7) · South Korea (7)
Danna Jennings, MD (4) · Craig van Horne, MD, PhD (3) · Nicolaas I Bohnen, MD, PhD (3) · Charles Oh, MD (2) · David Russell, MD (2) · David Russell, MD, PhD (2)
PMID 40680102, PMID 30741694, PMID 31127735, PMID 36602886, PMID 38588457, PMID 10816186, PMID 23860343, PMID 24412048, PMID 29862060, PMID 30361858, PMID 35949912, PMID 38072889, PMID 11408093, PMID 12112073, PMID 12672864, PMID 1362956, PMID 1454205, PMID 16324089, PMID 16941456, PMID 17586305, PMID 18387850, PMID 18416667, PMID 18650802, PMID 18695057, PMID 19029430, PMID 19077238, PMID 19230029, PMID 19491335, PMID 20065126, PMID 20213818, PMID 20228251, PMID 20734360, PMID 20925125, PMID 20946640, PMID 21474638, PMID 21484351, PMID 21795440, PMID 21834011, PMID 22334107, PMID 22401642, PMID 23229334, PMID 23240940, PMID 23576625, PMID 24006953, PMID 25689258, PMID 25791613, PMID 26171276, PMID 27153166, PMID 27213850, PMID 27591395
2014 (6), 2009 (2), 2015 (2), 2019 (2), 2025 (2), R01NS099535 (2), 2001 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1), I01RX003397 (1), IK2RX002938 (1), K01AT004404 (1), M01RR000096 (1)